Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.37 |
| ▸ | ESR1 | P03372 | 6/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12735849 | 0.92 | FPR2 (0.42) | KDM1ASCN9AESR1ESR2CYP3A4 | |
| SCHEMBL12735836 | 0.91 | KDM1A (0.45) | KDM1ASCN9AFPR2CNR2SCN5A | |
| SCHEMBL12735854 | 0.90 | KDM1A (0.44) | KDM1ASCN9AFPR2CNR2SCN5A | |
| SCHEMBL12735779 | 0.90 | CNR2 (0.38) | SCN9AESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL12740623 | 0.90 | CNR2 (0.38) | SCN9AESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL12821709 | 0.90 | KDM1A (0.41) | KDM1ASCN9AFPR2CNR2SCN5A | |
| SCHEMBL12735839 | 0.89 | KDM1A (0.44) | KDM1ASCN9ACYP2C9FPR2CNR2 | |
| SCHEMBL14766039 | 0.89 | KDM1A (0.44) | KDM1ASCN9AFPR2CNR2SGPL1 | |
| SCHEMBL14766014 | 0.89 | KDM1A (0.44) | KDM1ASCN9AFPR2CNR2SGPL1 | |
| SCHEMBL12740650 | 0.87 | FFAR1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | KDM1A 937/4885SCN9A 2503/4885ESR1 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.